Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Studies on mixing vaccines show 'high safety' says AIFA

Studies on mixing vaccines show 'high safety' says AIFA

'Tranquil' about following AZ with other jabs says Magrini

ROME, 16 June 2021, 12:50

Redazione ANSA

ANSACheck

- ALL RIGHTS RESERVED

-     ALL RIGHTS RESERVED
- ALL RIGHTS RESERVED

Clinical studies on mixing COVID-19 vaccines say this can be done with a high degree of safety, the head of Italian drugs agency AIFA told Italian radio Wednesday.
    Italy has banned the AstraZeneca jab for he under-60s and said those in this age bracket who have had a first dose of AZ will follow it with a Pfizer or Moderna jab.
    The science on mixing vaccines is based on "clinical studies which have been done with the utmost ethical rigour," and "the safety regarding the administration is very elevated", AIFA Director-General Nicola Magrini in remarks to Rainews24.
    "We must be more than tranquil" about following up an AZ jab with a Pfizer or Moderna one, he said.
    Magrini noted that "several other countries" had made the same decision due to a slim risk of blood clots after the AZ jab.
    The Italian decision on barring AZ for the under-60s came after the death from a cerebral haemorrhage after a blood clot of 18-year-old Italian woman Camilla Canepa.
    Magrini also said that adverse reactions to the Jonson & Johnson vaccine were less frequent than other ones.
   

ALL RIGHTS RESERVED © Copyright ANSA

Not to be missed

Share

Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.